News and Events

Jan 8, 2026 An HCRN study, HCRN-GI23-617, will be presented as a Trials in Progress poster at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026 in San Francisco. This study is led by Tiago Biachi de Castria, MD, PHD, of H. Lee Moffitt Cancer Center and Research Institute. Session Details: Poster Session B, on January 9, 11:30 am – 1:00 pm Presentation Title: Phase II study of NALIRIFOX (nanoliposomal irinotecan + oxaliplatin with fluorouracil and folinic acid)...

We are proud to see our CEO, Brian Stemme, featured in a BioCentury article highlighting Hoosier Cancer Research Network’s role in advancing multi-site investigator-initiated trials (IITs)- 

Hoosier Cancer Research Network is currently experiencing intermittent issues with our phone system. If your call is urgent or related to a patient in clinic, please contact your project manager directly. If you do not know your project manager’s cell number, please email our monitored project management inbox at projects@hoosiercancer.org.

August 12, 2025 Hoosier Cancer Research Network (HCRN) is proud to welcome nine new co-chairs across its clinical trial working groups. These accomplished leaders bring expertise, a dedication to investigator-initiated research, and a shared passion for teamwork that drives discovery forward. Through HCRN, investigators unite to propose clinical trials and share scientific insights. The leadership of these new co-chairs will strengthen the network’s efforts to foster team science and deliver innovative clinical trials to patients across the country.  

Dipenkumar Modi, MD, of the Karmanos Cancer Institute recently presented an interim analysis of the HCRN-LYM22-565 study at the European Hematology Association (EHA) 2025 Congress, held June 12–15 in Milan, Italy.

Hoosier Cancer Research Network is proud to share a recap of our experience at the 2025 American Society of Clinical Oncology® (ASCO) Annual Meeting. The review features highlights, key photos, notable moments, and insights into how we’re carrying the momentum of ASCO forward. About Hoosier Cancer Research Network: Hoosier Cancer Research Network conducts innovative cancer clinical trials in collaboration with more than 100 academic and community clinical research sites across the United States. Our studies are designed by cancer researchers...

Hoosier Cancer Research Network has released a new report, “Investigator-Initiated Oncology Trials: Trends, Challenges, and Opportunities,” that captures the experience and perspectives of more than 130 researchers across its nationwide network. The findings highlight key trends shaping investigator-initiated oncology research and the operational, institutional, and funding challenges researchers face in today’s environment. 

We are proud to see our CEO, Brian Stemme, featured in an Indiana Business Journal article as a trusted expert in Indiana’s life sciences ecosystem.

The University of Notre Dame will confer an honorary Doctor of Science degree on Hoosier Cancer Research Network (HCRN) co-founder Rafat Ansari, MD, at its 180th University Commencement Ceremony on May 18. A South Bend Community Hall of Fame inductee, Dr. Ansari has been a community leader in hematology and oncology for more than four decades. As a co-founder of HCRN, he was instrumental in streamlining the clinical trials process for cancer patients. Read more: https://news.nd.edu/news/notre-dame-to-confer-seven-honorary-degrees-at-commencement/

Hoosier Cancer Research Network (HCRN) is set to participate in the American Society of Clinical Oncology® (ASCO) 2025 Annual Meeting in Chicago from May 30 to June 3. During the event, four HCRN studies will be presented, working group meetings will take place, and HCRN will host a joint reception with the Big Ten Cancer Research Consortium. The HCRN team will also be present in the exhibit hall at booth # 36117.